2014, Number 6
<< Back Next >>
Med Int Mex 2014; 30 (6)
Calciphylaxis in the clinical practice: A report of a case with end stage chronic renal failure
Batún-Garrido JAJ, Hernández-Núñez É, Muñoz-Pérez H
Language: Spanish
References: 11
Page: 721-726
PDF size: 538.18 Kb.
ABSTRACT
Calciphylaxis is characterized by onset and fast progression of ischaemic
necrosis with cutaneous ulceration by deposit of calcium salts in the
middle layer of dermoepidermal arterioles. This entity has a high mortality
(60-80%), but a low incidence (1-4%). The gold standard testing
to confirm the diagnosis is the histological study. This paper reports the
case of a 64-year-old male patient with history of high blood pressure,
type 2 diabetes mellitus and terminal chronic renal failure, who began
this condition two weeks before his hospital admission with distal
paresthesias, then blisters in fingertips and right heel appeared that
progressed into necrotic ulceration. The patient fulfilled the clinical,
biochemical and radiologic criteria for this disease.
REFERENCES
Pérez J, Vargas J, Echeverría J, Rodríguez P, Pulido A. Calcifilaxis y enfermedad renal crónica. Acta Med Colomb 2011;36:149-152.
Scola N, Kreuter A. Calciphylaxis: a severe complication of renal disease. CMAJ 2011;183:1882.
Verdalles U, Verde E, García S, Goicochea M. Calcifilaxis: complicación grave del síndrome cardio-metabólico en pacientes con enfermedad renal crónica terminal (ERCT). Nefrología 2008;28:32-36.
Prados M, Pino M, Garófano R, Moriana C. Calcifilaxis severa en paciente en hemodiálisis. Dial Traspl 2010;31:76-78.
Kyttaris V, Timbil S, Kalliabakos D, Vaiopoulos G, Weinstein A. Calciphylaxis: a pseudo-vasculitis syndrome. Semin Arthritis Rheum 2006;36:264-267.
Weenig R, Sewell L, Davis M, McCarthy J, Pittelkow M. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007;56:569-579.
Gómez E, Vicente F, Álvarez J, Naz E, Palencia S. Calcifilaxis en pacientes dializados. Actas Dermosifiliogr 2004;95:178- 182.
Sowers K, Hayden M. Pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010;3:109-121.
Rodríguez N, Jiménez I, Méndez C, Canal C y col. Diagnóstico y tratamiento de las alteraciones oseominerales asociadas a la enfermedad renal crónica. Dial Traspl 2010;31:79-85.
Alborozi P, Patel N, Peterson C, Bills J, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-255.
Hervas J, Prados M, Polo A, Cerezo S. Efectividad del tratamiento con paricalcitol por vía oral en pacientes con enfermedad renal crónica en etapas anteriores a la diálisis. Nefrología 2011;31:697-706.
Full text